Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical (LFCR) Net Income towards Common Stockholders: 2009-2025

Historic Net Income towards Common Stockholders for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to -$2.0 million.

  • Lifecore Biomedical's Net Income towards Common Stockholders rose 71.10% to -$2.0 million in Q2 2025 from the same period last year, while for May 2025 it was -$44.4 million, marking a year-over-year decrease of 12610.32%. This contributed to the annual value of -$44.4 million for FY2025, which is 469.26% down from last year.
  • Lifecore Biomedical's Net Income towards Common Stockholders amounted to -$2.0 million in Q2 2025, which was up 88.22% from -$17.4 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's Net Income towards Common Stockholders ranged from a high of $15.6 million in Q1 2024 and a low of -$51.6 million during Q2 2022.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$7.9 million (2024), whereas its average is -$7.2 million.
  • In the last 5 years, Lifecore Biomedical's Net Income towards Common Stockholders tumbled by 2,376.79% in 2022 and then spiked by 162.09% in 2024.
  • Lifecore Biomedical's Net Income towards Common Stockholders (Quarterly) stood at -$46.0 million in 2021, then skyrocketed by 92.17% to -$3.6 million in 2022, then slumped by 198.31% to -$10.8 million in 2023, then grew by 19.07% to -$8.7 million in 2024, then skyrocketed by 71.10% to -$2.0 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$2.0 million for Q2 2025, versus -$17.4 million for Q1 2025 and -$8.7 million for Q4 2024.